Role of Perfusion CT in Pancreatic Cancer

Seoul National University

Status

Unknown

Conditions

Adenocarcinoma, Pancreas

Neuroendocrine Carcinoma of Pancreas

Treatments

Procedure: CT

Drug: iopromide

Study type

Observational

Funder types

Other

Identifiers

SNUH_ISS_2012

Details and patient eligibility

About

The purpose of this study is

to determine whether the perfusion parameters in the normal pancreas and the pancreas cancer (adenocarcinoma or neuroendocrine tumor) are different on perfusion CT
to determine whether initial perfusion parameters as well as perfusion parameter change in pancreas adenocarcinoma before and after chemotherapy are different between chemotherapy response group (CR, PR according to RECIST 1.1) and non response group (SD, PD according to RECIST 1.1).

Full description

Performance of preoperative perfusion CT for preoperative staging is assessed by comparing with operative finding and histologic disease staging
Estimation of initial or change of pancreas cancer perfusion parameters and whether those can provide cut-off value for predicting response of chemotherapy in patients with pancreas adenocarcinoma

Enrollment

48 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients who are older than eighteen years
patients in whom operation and preoperative computed tomography are scheduled for resectable pancreas adenocarcinoma or pancreas neuroendocrine tumor
patients in whom chemotherapy is scheduled for histologically confirmed pancreas adenocarcinoma
patients in whom chemotherapy is planned for highly suspicious pancreas adenocarcinoma on imaging workup
patients who agree with the study and whose informed consent is obtained.

Exclusion criteria

patients who are younger than eighteen years old
patients in whom previously radiation therapy was performed and the RTx field includes pancreas
patients with recurred pancreas adenocarcinoma
patient who are pregnant or nursing patients
patients with renal failure (GFR<30mL/min)
patients with history of malignancy, except malignancy is in complete remission after operation or iodine therapy for at least five years)
patients with hypersensitivity for iodine or contrast media or other causes of contraindication of contrast-media enhanced CT scan
Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the completion of the study.